The Wegovy pill, priced and read against its own trial
The first oral GLP-1 approved for weight loss is real, cheap to start, and more expensive than the headline once you reach the treatment dose. Here is the whole picture.
FDA approved Wegovy tablets (oral semaglutide 25 mg) on December 22, 2025 — the first oral GLP-1 for chronic weight management. It launched nationally on January 5, 2026 at $149 per month self-pay for the 1.5 mg starting dose. In the OASIS 4 trial, participants averaged 13.6% weight loss at 64 weeks (16.6% among those who stayed on treatment). The catch is dose-tier pricing: the 9 mg and 25 mg maintenance doses run about $299 per month cash through major channels.
- What OASIS 4 actually showed: OASIS 4 was a 64-week randomized, double-blind, placebo-controlled trial in 307 adults with obesity, or overweight plus at least one weight-related....
- Pill versus injection: The 16.6 percent adherent-population figure is broadly in line with injectable Wegovy 2.4 mg, which produced 14.9 percent average loss in STEP-1.
- The dose-tier pricing nobody puts in the headline: The $149 launch price applies to the 1.5 mg starting dose.
- Where you can actually get it: Novo launched wide: the pill is stocked through more than 70,000 U.S.
- What it means for compounded semaglutide: Compounded oral semaglutide products — the ODT tablets and sublingual drops sold by some telehealth programs — now compete against an FDA-approved ....
What OASIS 4 actually showed
OASIS 4 was a 64-week randomized, double-blind, placebo-controlled trial in 307 adults with obesity, or overweight plus at least one weight-related condition; people with diabetes were excluded. On the treatment-policy analysis — everyone randomized, regardless of whether they stayed on the drug — oral semaglutide 25 mg produced 13.6 percent mean weight loss versus 2.4 percent with placebo. Among participants who adhered to treatment, the average was 16.6 percent.
Two secondary findings matter for real decisions. About one-third of adherent participants lost at least 20 percent of body weight. And among participants with prediabetes at baseline, 71 percent reached normal blood glucose versus 33 percent on placebo. Serious adverse events were actually less frequent on semaglutide than placebo (3.9 versus 8.8 percent); the common side effects were the familiar GLP-1 trio of nausea, diarrhea and vomiting.
| Dose | Role | Cash price/mo | Channel notes |
|---|---|---|---|
| 1.5 mg | Starting dose | $149 | Launch price; savings offers |
| 4 mg | Titration | $149–$199 | $149 via GoodRx through Apr 15, 2026 |
| 9 mg | Titration | $299 | GoodRx / NovoCare |
| 25 mg | Treatment dose | $299 | GoodRx / NovoCare; OASIS 4 dose |
| Insured copay | Any covered dose | ~$25 | Commercial savings program, eligibility required |
Pill versus injection: the honest comparison
The 16.6 percent adherent-population figure is broadly in line with injectable Wegovy 2.4 mg, which produced 14.9 percent average loss in STEP-1. It remains below injectable tirzepatide, which averaged 20.9 percent at the top dose in SURMOUNT-1 and beat semaglutide directly in SURMOUNT-5. If maximum weight loss is the only criterion, the pill is not the leader.
The pill wins on logistics: no needles, no refrigeration, and a familiar daily-tablet routine. It loses on one ritual — the tablet must be taken on an empty stomach with a small amount of water, followed by a 30-minute wait before eating or other medications. In practice that constraint is the most common adherence complaint with oral semaglutide, and it is worth being honest with yourself about before choosing the pill for convenience.
The dose-tier pricing nobody puts in the headline
The $149 launch price applies to the 1.5 mg starting dose. Wegovy tablets come in 1.5, 4, 9 and 25 mg strengths, and titration to the 25 mg treatment dose is the intended path — OASIS 4 escalated over 12 weeks. Through GoodRx, the 1.5 and 4 mg doses are $149 through April 15, 2026 (then $199 for 4 mg), while the 9 and 25 mg doses are $299 per month. Novo's own savings offers put commercially insured copays potentially as low as $25.
So the realistic self-pay year is not 12 × $149. A typical titration — three months at starter tiers and nine months at the 25 mg dose — lands around $2,900 to $3,200 for year one, before any clinic or lab fees from the prescribing channel. That is materially cheaper than brand injectable retail, comparable to Wegovy injection's $349–$499 self-pay tiers, and still above the lowest verified compounded semaglutide programs in our database.
Where you can actually get it
Novo launched wide: the pill is stocked through more than 70,000 U.S. pharmacies including CVS and Costco, through NovoCare Pharmacy, and through telehealth partners including Ro, LifeMD and WeightWatchers. GoodRx added it to its weight-loss telehealth subscription in January 2026, matching the $149 launch price on starter doses.
A prescription is required in every channel, and the eligibility criteria mirror injectable Wegovy: BMI of 30 or higher, or 27 with at least one weight-related condition. On the insurance side, CVS Caremark lists both the Wegovy injection and pill as preferred options on its standard commercial formularies — subject, as always, to whether your plan sponsor covers weight-loss medication at all.
What it means for compounded semaglutide
Compounded oral semaglutide products — the ODT tablets and sublingual drops sold by some telehealth programs — now compete against an FDA-approved pill with published Phase III evidence at a $149 entry price. Our position on compounded ODT products has not changed: no published trial evidence supports their bioavailability claims, and several are priced above the approved pill's starter dose. The approved tablet makes that segment very hard to justify.
Compounded injectable semaglutide is a different calculation. The lowest verified programs in our pricing database still undercut the pill's maintenance-dose cost by $100 or more per month at treatment doses, which will keep that market alive for cash-pay patients — with the standing caveat that compounded drugs are not FDA-approved and post-2025 enforcement limits how they can legally be produced.
Who the pill fits, and who it does not
The pill is a strong fit for needle-averse patients, for people who travel and cannot refrigerate pens, and for anyone whose insurance copay lands near $25. It is a weaker fit if you struggle with a fasting-window routine, if you are chasing maximum weight loss and tolerate injections well, or if you take multiple morning medications whose timing conflicts with the 30-minute rule.
Switching is supported in both directions: Novo's labeling allows moving from the 25 mg tablet to the 2.4 mg weekly injection starting the day after the last pill. Any switch — including from compounded semaglutide to the approved pill — should run through your prescriber, because dose equivalence between routes is not one-to-one.
Frequently asked questions
Is the Wegovy pill the same as Rybelsus?
Same molecule, different product. Rybelsus is oral semaglutide approved for type 2 diabetes at doses up to 14 mg; the Wegovy pill is a 25 mg formulation approved December 2025 specifically for weight management.
Does the $149 price last?
$149 is the launch self-pay price for the starting dose. Maintenance doses run about $299 cash, and promotional windows (like GoodRx's starter pricing) have stated end dates. Treat $149 as an entry price, not your steady-state cost.
Is the pill as effective as the injection?
Adherent-population results (16.6%) are similar to injectable Wegovy's trial average and below injectable tirzepatide's. Individual response varies; route of administration matters less than staying on a dose you tolerate.